Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 13/20 | 0.38 |
| ▸ | KDR | P35968 | 13/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 10/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 5/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22074968 | 1.00 | FGFR3 (0.38) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL30579112 | 0.91 | FGFR3 (0.39) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22075194 | 0.91 | FGFR3 (0.39) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22075038 | 0.90 | FGFR3 (0.39) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL30579208 | 0.90 | FGFR3 (0.39) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22075330 | 0.89 | FEN1 (0.39) | KDRFEN1METPDK2 | |
| SCHEMBL22075117 | 0.83 | MET (0.39) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL30579101 | 0.83 | MET (0.39) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL25084693 | 0.82 | TGFBR1 (0.41) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22075160 | 0.82 | FGFR3 (0.40) | FGFR3KDRFGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730720-B2 | ALK5 inhibitors | ALK, ACVR1, ACVRL1 | FGFR3 189/4885KDR 69/4885FGFR1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.